It is an honor and a privilege to lead such a talented and committed team as Arvinas enters a period where we anticipate ...
Arvinas (NASDAQ:ARVN) executives used the company’s fourth-quarter and full-year 2025 earnings call to outline a strategy centered on advancing four Phase 1 clinical programs and preparing for ...
Q4 2025 earnings call recap: pipeline milestones, PROTAC FDA/PDUFA timeline, 2026 data catalysts, and cash runway—read now.
NEW HAVEN, Conn., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...
Company entering 2026 with the potential to deliver multiple value-driving milestones, including data readouts from ARV-102, ARV-806, and ...
Arvinas, Inc. announced that it will present new preclinical data on its investigational oral PROTAC BCL6 degrader, ARV-393, at the upcoming European Hematology Association (EHA) meeting in Milan from ...
Arvinas, Inc. announced promising preclinical results for ARV-393, a targeted protein degrader aimed at treating non-Hodgkin lymphoma, particularly high grade B-cell lymphomas. Data showed that ...
Arvinas, Inc. (NASDAQ:ARVN) unveiled first-in-human data on Friday for its experimental Parkinson’s disease treatment, ARV-102. Results from the randomized, double-blind, placebo-controlled single ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results